Intrinsiqq
⚠ Showing the latest available close (Oct 21, 2026, 2 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.
Cannabis Bioscience International Inc. logoCannabis Bioscience International Inc.CBIH
$0.0002+0.00%
Cannabis Bioscience International Inc. logo

Cannabis Bioscience International Inc.

CBIH

$0.00

+$0.00 (+0.00%)

⊜ Compare
ProfitabilityUnprofitableGrowthAcceleratingCash FlowN/AValuationN/A
What stands out

The business is unprofitable at the operating level (-139.05% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.

What's changing

Revenue up 21.8% YoY with margins expanding 56.3pp.

What deserves caution

Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.

Price History

-60.0%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$2M
EPS-$0.00
P/E-4.55
P/FCF—
EV/EBITDA-6.49
FCF Yield—
Div. Yield—
Net Debt/FCF—
52-Week Range
$0.00$0.00

Profitability & Returns

Revenue (TTM)

$124K

▲ +21.8% YoY

Net Income (TTM)

-$515K

▲ +15.7% YoY

Op. Margin

-322.60%

▲ +56.3pp YoY

ROIC

-118.67%

▲ +18.6pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$268K

▲ +31.2% YoY

Net Debt

$264K

Cash & Equiv.

$90.00

Continue Research

SourceComputed from the 10-Q filed 16 Apr 2026, covering the period ending 28 Feb 2026, as reported to the SEC. Data last refreshed 7 Jun 2026. How this is calculated.

Price from market data, last close as of 21 Oct 2026. Fiscal year ends May. Sector medians are approximate S&P 500 benchmarks and update periodically.

Is Cannabis Bioscience International (CBIH) overvalued?

Cannabis Bioscience International (CBIH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Cannabis Bioscience International scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

Is Cannabis Bioscience International a high-quality business?+

Cannabis Bioscience International scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -322.6% operating margin and a -118.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Is Cannabis Bioscience International a good stock to buy right now?+

That depends on valuation and quality together, not either alone. you should weigh CBIH's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.

Related stocks: Services-Commercial Physical & Biological Research

Spot a number that looks wrong? Check it in CBIH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CBIH

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.